Jennifer Fitzpatrick sold $415k of SION
Chief Legal Officer at Sionna Therapeutics, Inc.. 10,250 shares at an average of $40.52, traded Dec 5, 2025, filed Dec 9, 2025.
Score components
- +15RoleOfficer
- +16Trade size$415k at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0002061851-25-000003, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 5, 2025 | MOption exercise Common Stock10b5-1 | +10,250 | $6.11 | $63k | 10,250 | Dec 9, 2025 |
| Dec 5, 2025 | SOpen-market sale Common Stock10b5-1 | -10,250 | $40.52 | $415k | 0 | Dec 9, 2025 |
| Dec 5, 2025 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -10,250 | $0.00 | $0 | 61,185 | Dec 9, 2025 |
Related signals
Other insiders at Sionna Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | SIONsell Sionna Therapeutics, Inc. | Ra Capital Management, L.p. director, owner | $22M 3,448,811 shares | -50% | |
| 28Weak | Sionna Therapeutics, Inc. | Orbimed Advisors LLC director | $1.5M 33,356 shares | -1% | |
| 28Weak | Sionna Therapeutics, Inc. | Peter A. Thompson director | $1.5M 33,356 shares | -1% | |
| 19Weak | Sionna Therapeutics, Inc. | Orbimed Advisors LLC director | $83k 1,875 shares | -0% | |
| 19Weak | Sionna Therapeutics, Inc. | Peter A. Thompson director | $83k 1,875 shares | -0% | |
| 35Weak | Sionna Therapeutics, Inc. | Orbimed Advisors LLC director | $4.8M 108,073 shares | -3% | |
| 35Weak | Sionna Therapeutics, Inc. | Peter A. Thompson director | $4.8M 108,073 shares | -3% | |
| 55Moderate | Sionna Therapeutics, Inc. | Ra Capital Management, L.p. director, owner | $1.2M 30,316 shares | -0% | |
| 55Moderate | Sionna Therapeutics, Inc. | Ra Capital Management, L.p. director, owner | $5.5M 136,351 shares | -2% | |
| 55Moderate | Sionna Therapeutics, Inc. | Ra Capital Management, L.p. director, owner | $15M 373,610 shares | -5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.